Bioequivalence Testing Is First Step In China’s Pharma Industry Upgrade – RDPAC
This article was originally published in PharmAsia News
Executive Summary
Time is tight for China to complete an ambitious generic bioequivalence testing schedule, and the stakes couldn’t be higher for the industry, a top executive of the leading trade association in China says.
You may also be interested in...
What Multinational Companies Need To Know About China's New GMP Regs - Webinar (Part 2 of 2)
SHANGHAI - China's new good manufacturing practices regulations that went into effect March 1 significantly raise drug manufacturing standards in almost all areas, and shift the focus of China GMPs to a risk-based quality approach. But more importantly, the new regs indicate how China's State FDA views GMPs and the specific areas that will see more regulatory focus
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.